Short-term therapy with oral olpadronate in active Paget's disease of bone

Journal of Bone and Mineral Research

Volumn 14, Issue 12, 1999, Pages 2042-2047

  González, Diana C ^a   Mautalen, Carlos A ^a  

^a Ctro de Osteopatias Medicas   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; ETIDRONIC ACID; OLPADRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PAGET BONE DISEASE; STOMACH DISEASE;

EID: 0343920813     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1999.14.12.2042     Document Type: Article

References (33)

1. Siris E 1998 Clinical Review: Paget's disease of bone. J Bone Miner Res 13:1061-1065.
2. Papapoulos S 1997 Paget's disease of bone: Clinical, pathogenetic and therapeutic aspects. Bailliere's Clin Endocrinol Metab 11(1):117-143.
3. Boonekamp PM, Löwik C, van der Wee-Pals L, van Wijk-van Leenep ML, Bijvoet O 1987 Enhancement of the inhibitory action of APD on the transformation of osteoclasts precursors into resorting cells after dimethylation of the amino group. Bone Miner 2:29-42.
4. Vega E, Mautalen C, Roldán EJ, Pérez Lloret A 1994 Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile. Drugs Exp Clin Res 20:103-108.
5. González D, Pastrana M, Mautalen C 1997 Tratamiento de la enfermedad de Paget con olpadronato: Su eficacia terapéutica en respondedores parciales al pamidronato oral. Medicina (Buenos Aires) 57 (Suppl 1):25-31.
6. Fleisch H 1997 Bisphosphonates in bone disease. From the Laboratory to the Patient, 3rd Ed. The Parthenon Publishing Group Ltd, Carnforth, New York, U.S.A., pp. 45-46.
7. Schweitzer D, Zwinderman A, Vermeli Bijvoet O, Papapoulos S 1993 Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 8:175-182.
8. Behr W, Barnett J 1986 Quantification of bone alkaline phosphatase in serum by precipitation with wheat germ lectin a simplified method and its clinical plausibility. Clin Chem 32:1960-1966.
9. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1995 Application of an enzyme immunoassay for a new marker of bone resorption (crosslaps): Follow up on hormone replacement therapy and osteoporotic risk fracture. J Clin Endocrinol Metab 80:864-868.
10. Papapoulos S, Frölich M 1996 Predition of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. J Clin Endocrinol Metab 81:3993-3997.
11. Kanis JA 1991 Management and assessment of response. In: Fogelman I (ed.) Pathophysiology and Treatment of Paget's Disease of Bone, Martin Dunitz, London, U.K., pp. 217-251.
12. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy W, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci J, Yates A, Zimering M 1996 Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81:961-967.
13. Mautalen C, González D, Ghiringhelli G 1985 Efficacy of the bisphosphonate APD in the control of Paget's bone disease. Bone 6:429-432.
14. Patel S, Stone MD, Coupland C, Hosking D 1993 Determinants of remission of Paget's disease of bone. J Bone Miner Res 8:1467-1473.
15. Wimalawansa SJ, Gunasekera R 1993 Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. Calcif Tissue Int 53:237-241.
16. Harinck HJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM 1987 Paget's disease of bone early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J 295:1301-1305.
17. Singer F, Clemens T, Eusebio R, Bekker P 1998 Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 83:1906-1910.
18. Cundy T, Wattie D, King AR 1996 High-dose pamidronate in the management of resistant Paget's disease. Calcif Tissue Int 58:6-8.
19. Gertz BJ, Holland SD, Kline WF, Matuzewski BK, Porras AG 1993 Clinical pharmacology of alendronate sodium. Osteoporos Int 3 (Suppl 3):513-516.
20. Mautalen C, González D, Blumenfeld E, Santini Araujo E, Schajowicz F 1986 Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP). Clin Orthop 207:150-153.
21. Adamson B, Gallacher S, Byaars J, Ralston S, Boyle I, Boyce B 1993 Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 342:1459-1460.
22. Blumsohn A, Naylor K, Assiri A, Eastell R 1995 Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin Chem 41:1592-1598.
23. De la Piedra C, Rapado A, Díaz Diego E, Díaz Martín M, Aguirre C, López Gavilanes E, Díaz Curiel M 1996 Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate. Calcif Tissue Int 59:95-99.
24. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse H, Picot C, Tieux L, Reginster JY, Dougados M 1995 Comparative prospective double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 38:851-858.
25. McClung MR, Tou CKP, Goldstein NH, Picot C 1995 Tiludronate therapy for Paget's disease of bone. Bone 17:493S-496S.
26. Khan SA, Vasikaran S, McCloskey Benéton MN, Rogers S, Coulton S, Ogee J, Coombes G, Kanis JA 1997 Alendronate in the treatment of Paget's disease of bone. Bone 20:263-271.
27. Adami S, Mian M, Gatti P, Rossini M, Zamberlan N, Bertoldo F, Lo Cascio V 1994 Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 15:415-417.
28. Siris E, Chines A, Altman R, Brown J, Johnston C, Lang RMC, Clung M, Mallette L, Miller P, Ryan W, Singer F, Tucci J, Eusebio R, Bekker P 1998 Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study. J Bone Miner Res 13:1032-1038.
29. Hosking DDJ, Eusebio R, Chines AA 1998 Paget's disease of bone: Reduction of disease activity with oral risedronate. Bone 22:51-55.
30. Hosking DJ 1999 Prediction and assessment of the response of Paget's disease to bisphosphonate treatment. Bone 24 (Suppl):69S-71S.
31. Devogelaer JP, Malghem J, Stasse P, Nagant De Deuxchaisnes C 1997 Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone. Bone 20:259-261.
32. Hydlstrup L, Flesch G, Hauffe SA 1993 Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif Tissue Int 53:297-300.
33. Roldan EJA, Mondelo N, Piccinni E, Peluffo V, Montuori E 1995 Olpadronic acid sodium salt IG-8801: Treatment for Paget's bone disease. Treatment for osteoporosis. Drugs Future 20:1123-1127.